Literature DB >> 11369659

CD44 ligation on peripheral blood polymorphonuclear cells induces interleukin-6 production.

G Sconocchia1, L Campagnano, D Adorno, A Iacona, N Y Cococcetta, V Boffo, S Amadori, C U Casciani.   

Abstract

Polymorphonuclear cells (PMNs) contribute to the initiation and progression of the immune response by mediating cytotoxicity, phagocytosis, and cytokine secretion. Because CD44 serves as a cytotoxic-triggering molecule on PMNs, it was hypothesized that it could also trigger cytokine production. In this study, the effect of anti-CD44 antibodies on interleukin-6 (IL-6) production in human PMNs was assessed. By using a reverse transcriptase-polymerase chain reaction, it was shown that PMNs stimulated with a mouse monoclonal or a rabbit polyclonal F(ab)(2) anti-CD44 transcribe IL-6 messenger RNA. A similar effect was obtained when an anti-CD44 antibody was replaced with hyaluronic acid (HA). Kinetic studies showed that anti-CD44 and HA induced IL-6 gene transcription, initiated 3 hours after stimulation, peaked between 12 and 24 hours, and disappeared after 48 hours. Analogous results were achieved when secreted IL-6 protein was measured by enzyme-linked immunosorbent assay in the PMN culture supernatants. To characterize which metabolic pathways regulated CD44-dependent IL-6 production in PMNs, an RNA polymerase inhibitor, actinomycin D, and 2 protein kinase inhibitors, such as genistein and staurosporine, were tested. Actinomycin D and genistein blocked IL-6 production, whereas staurosporine did not, suggesting that CD44-dependent IL-6 production requires gene transcription and tyrosine kinase activity. Furthermore, the relationship between CD44 and cytokines that affect PMN function, including interferon gamma (IFNgamma) and IL-2, was investigated. Without CD44 cross-linking, IFNgamma did not trigger IL-6 production. However, on CD44 cross-linking, IFNgamma produced a strong synergistic effect on IL-6 syntheses in human PMNs. (Blood. 2001;97:3621-3627)

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11369659     DOI: 10.1182/blood.v97.11.3621

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  12 in total

1.  CD44 deficiency leads to enhanced neutrophil migration and lung injury in Escherichia coli pneumonia in mice.

Authors:  Qin Wang; Priit Teder; Nancy P Judd; Paul W Noble; Claire M Doerschuk
Journal:  Am J Pathol       Date:  2002-12       Impact factor: 4.307

2.  HLA class II antigen expression in colorectal carcinoma tumors as a favorable prognostic marker.

Authors:  Giuseppe Sconocchia; Serenella Eppenberger-Castori; Inti Zlobec; Eva Karamitopoulou; Roberto Arriga; Andrea Coppola; Sara Caratelli; Giulio Cesare Spagnoli; Davide Lauro; Alessandro Lugli; Junyi Han; Giandomenica Iezzi; Cristina Ferrone; Amedeo Ferlosio; Luigi Tornillo; Raoul Droeser; Piero Rossi; Antonio Attanasio; Soldano Ferrone; Luigi Terracciano
Journal:  Neoplasia       Date:  2014-01       Impact factor: 5.715

Review 3.  Hyaluronan as an immune regulator in human diseases.

Authors:  Dianhua Jiang; Jiurong Liang; Paul W Noble
Journal:  Physiol Rev       Date:  2011-01       Impact factor: 37.312

4.  Direct CD32 T-cell cytotoxicity: implications for breast cancer prognosis and treatment.

Authors:  Giuseppe Sconocchia; Giulia Lanzilli; Valeriana Cesarini; Domenico A Silvestris; Katayoun Rezvani; Roberto Arriga; Sara Caratelli; Ken Chen; Jinzhuang Dou; Carlo Cenciarelli; Gabriele Toietta; Silvia Baldari; Tommaso Sconocchia; Francesca De Paolis; Anna Aureli; Giandomenica Iezzi; Maria Irno Consalvo; Francesco Buccisano; Maria I Del Principe; Luca Maurillo; Adriano Venditti; Alessio Ottaviani; Giulio C Spagnoli
Journal:  Life Sci Alliance       Date:  2022-10-14

5.  Host and pathogen hyaluronan signal through human siglec-9 to suppress neutrophil activation.

Authors:  Ismael Secundino; Anel Lizcano; K Markus Roupé; Xiaoxia Wang; Jason N Cole; Joshua Olson; S Raza Ali; Samira Dahesh; Lenah K Amayreh; Anna Henningham; Ajit Varki; Victor Nizet
Journal:  J Mol Med (Berl)       Date:  2015-09-28       Impact factor: 4.599

6.  CD16-158-valine chimeric receptor T cells overcome the resistance of KRAS-mutated colorectal carcinoma cells to cetuximab.

Authors:  Roberto Arriga; Sara Caratelli; Giulia Lanzilli; Alessio Ottaviani; Carlo Cenciarelli; Tommaso Sconocchia; Giulio C Spagnoli; Giandomenica Iezzi; Mario Roselli; Davide Lauro; Andrea Coppola; Gianpietro Dotti; Soldano Ferrone; Giuseppe Sconocchia
Journal:  Int J Cancer       Date:  2019-08-30       Impact factor: 7.396

7.  In vitro elimination of epidermal growth factor receptor-overexpressing cancer cells by CD32A-chimeric receptor T cells in combination with cetuximab or panitumumab.

Authors:  Sara Caratelli; Roberto Arriga; Tommaso Sconocchia; Alessio Ottaviani; Giulia Lanzilli; Donatella Pastore; Carlo Cenciarelli; Adriano Venditti; Maria Ilaria Del Principe; Davide Lauro; Elisa Landoni; Hongwei Du; Barbara Savoldo; Soldano Ferrone; Gianpietro Dotti; Giuseppe Sconocchia
Journal:  Int J Cancer       Date:  2019-10-12       Impact factor: 7.396

8.  A role for the endothelial glycosaminoglycan hyaluronan in neutrophil recruitment by endothelial cells cultured for prolonged periods.

Authors:  Lynn M Butler; G Ed Rainger; Gerard B Nash
Journal:  Exp Cell Res       Date:  2009-08-28       Impact factor: 3.905

9.  Activated polymorphonuclear leukocytes rapidly synthesize retinoic acid receptor-alpha: a mechanism for translational control of transcriptional events.

Authors:  Christian C Yost; Melvin M Denis; Stephan Lindemann; Frederick J Rubner; Gopal K Marathe; Michael Buerke; Thomas M McIntyre; Andrew S Weyrich; Guy A Zimmerman
Journal:  J Exp Med       Date:  2004-08-30       Impact factor: 14.307

10.  Efficacy of treatment with glycosaminoglycans on experimental collagen-induced arthritis in rats.

Authors:  Giuseppe M Campo; Angela Avenoso; Salvatore Campo; Alida M Ferlazzo; Domenica Altavilla; Alberto Calatroni
Journal:  Arthritis Res Ther       Date:  2003-03-06       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.